RecruitingPhase 3NCT06344442

Low-dose Arginine-vasopressin Supplementation on Post-transplant Acute Kidney Injury After Liver Transplantation (AVENIR Trial)

Studying Acute graft versus host disease

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Assistance Publique - Hôpitaux de Paris
Principal Investigator
Jacques DURANTEAU, Pr
Département Anesthésie-Réanimation - Université Paris-Saclay Hospital Bicêtre - Paul Brousse
Intervention
Arginine vasopressin(drug)
Enrollment
304 target
Eligibility
18 years · All sexes
Timeline
2025 – 2027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06344442 on ClinicalTrials.gov

Other trials for Acute graft versus host disease

Additional recruiting or active studies for the same condition.

See all trials for Acute graft versus host disease →

← Back to all trials